The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

Carsten Goessl(Amgen (United States)), Rachel B. Wagman(Amgen (United States)), William C. Dougall(Amgen (United States)), Leonid Katz(Amgen (United States)), Holly Brenza Zoog(Amgen (United States)), Paul J. Kostenuik(Amgen (United States)), Ada Braun(Amgen (United States)), Roger Dansey(Memorial Sloan Kettering Cancer Center)
Annals of the New York Academy of Sciences
July 25, 2012
10.1111/j.1749-6632.2012.06674.x
Cited by 41

Related Papers

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
RANK is essential for osteoclast and lymph node development
|Genes & Development|1999|1.5k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k